Podcasts about medical oncology

Indolent systemic mastocytosis (ISM) is a rare form of systemic mastocytosis (SM) caused by an abnormal buildup of mast cells throughout the body. What causes ISM, and how is it diagnosed? In this episode, we speak with Aaron Gerds, MD, Associate Professor of Medicine in Hematology and Medical Oncology at the Cleveland Clinic Cancer Institute, about the signs and symptoms of ISM, the diagnostic process, and how ISM differs from other forms of systemic mastocytosis. We also hear from Candice Pauley, an ISM patient and co-host of the Mast Cast Pod, who shares her journey to diagnosis, her experience living with the disease, and the challenges of navigating a rare condition. Credits Host: Neha Pathak, MD, FACP, DipABLM Producer/Editor: Matt Stillo Show Notes: Lauren Summers Guests: Aaron Gerds, MD; Candice Pauley See omnystudio.com/listener for privacy information.

As cancer incidences continue to rise across the country. The Presidents of Ireland's cancer care representative bodies, along with the Irish Cancer Society, are warning that key parts of the care system are struggling to keep pace. Speaking to Anton was Dr Michael McCarthy the President of the Irish Society for Medical Oncology and is a signatory on the joint letter.

As cancer incidences continue to rise across the country. The Presidents of Ireland's cancer care representative bodies, along with the Irish Cancer Society, are warning that key parts of the care system are struggling to keep pace. Speaking to Anton was Dr Michael McCarthy the President of the Irish Society for Medical Oncology and is a signatory on the joint letter.

In today's episode, we welcomed Charles E. Geyer, MD, to discuss recent FDA approvals of fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) for the management of HER2-positive breast cancer. Dr Geyer is a professor of medicine and chief of Malignant Hematology and Medical Oncology in the Department of Medicine at the University of Pittsburgh and the University of Pittsburgh Medical Center Hillman Cancer Center in Pennsylvania.On May 15, 2026, the FDA approved T-DXd for the neoadjuvant treatment of adult patients with HER2-positive stage II or III breast cancer, as determined by an FDA-authorized test, followed by a taxane, trastuzumab (Herceptin), and pertuzumab (Perjeta); the regulatory agency simultaneously approved post-neoadjuvant T-DXd for the treatment of adult patients with HER2-positive breast cancer who have residual invasive disease after neoadjuvant HER2-targeted treatment.In our exclusive interview, Dr Geyer discussed the significance of these approvals, key data from the pivotal trials, and how these new indications for T-DXd are shaking up the HER2-positive breast cancer treatment paradigm.

Featuring perspectives from Dr Lyudmila Bazhenova and Dr Corey J Langer, including the following topics: Introduction (0:00) Therapeutic Approaches Targeting HER2 and RET — Dr Bazhenova (9:09) Therapeutic Approaches Targeting ALK and ROS1 — Dr Langer (31:56) CME information and select publications

Featuring perspectives from Dr Erika Hamilton, Dr Jane Lowe Meisel, Dr Joyce O'Shaughnessy and Dr Seth Wander, including the following topics: Introduction (0:00) Current and Future Management of HR-Positive, HER2-Negative Localized Breast Cancer — Dr Meisel(2:40) Optimizing First-Line Therapy for Patients with HR-Positive Metastatic Breast Cancer (mBC) — Dr Hamilton (36:57) Current and Future Role of Oral Selective Estrogen Receptor Degraders for Progressive HR-Positive mBC — Dr Wander (58:18) Clinical Utility of Agents Targeting the PI3K/AKT/mTOR Pathway for Patients with Progressive HR-Positive mBC — Dr O'Shaughnessy (1:18:00) CME information and select publications

Featuring perspectives from Dr Courtney D DiNardo and Dr Harry Paul Erba, including the following topics: Introduction (0:00) Current Management Approaches for FLT3- and IDH-Mutated Acute Myeloid Leukemia (AML) — Dr DiNardo (9:44) Current and Future Role of Menin Inhibitors for Patients with AML — Dr Erba (32:07) CME information and select publications

Featuring perspectives from Dr Jonathan Goldman and Dr Zofia Piotrowska, including the following topics: Introduction (0:00) Current Management of Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) — Dr Goldman (0:38) Nonmetastatic EGFR-Mutated NSCLC, Exon 20 Insertion Mutations and Novel Agents — Dr Piotrowska (33:20) CME information and select publications

Featuring perspectives from Dr Mrinal Gounder and Dr Richard F Riedel, including the following topics: Introduction (0:00) Desmoid Tumors — Dr Gounder (2:58) Soft Tissue Sarcoma — Dr Riedel (28:29) CME information and select publications

Featuring perspectives from Dr Anthony M Hunter and Dr Abdulraheem Yacoub, including the following topics: Introduction (0:00) Systemic Mastocytosis — Dr Hunter (9:33) Myelofibrosis — Dr Yacoub (29:40) CME information and select publications

Guest: Urs Weber, MD For patients with ALK-positive non-small cell lung cancer, staying on therapy often means staying ahead of treatment-related toxicities. Join Dr. Urs Weber, Assistant Professor in the Division of Medical Oncology at the University of Colorado Anschutz Medical Campus, as he explores practical strategies for toxicity management, dose optimization, and shared decision-making to help support durable outcomes.

Guest: Urs Weber, MD Advances in targeted therapies have dramatically improved outcomes for patients with ALK-positive non-small cell lung cancer, but new resistance challenges continue to emerge. In this episode, Dr. Urs Weber discusses how cancers adapt to treatment, why off-target resistance and histologic transformation are becoming increasingly important, and where future research may help close critical gaps in care. Dr. Weber is an Assistant Professor in the Division of Medical Oncology at the University of Colorado Anschutz Medical Campus.

Guest: Urs Weber, MD As outcomes improve for patients with ALK+ non-small cell lung cancer, attention is shifting toward therapies designed to push disease control even further. Tune in as Dr. Urs Weber examines promising agents in development and discusses the momentum driving the next phase of ALK-targeted treatment. Dr. Weber is an Assistant Professor in the Division of Medical Oncology at the University of Colorado Anschutz Medical Campus.

Featuring perspectives from Dr Neeraj Agarwal and Dr Alan H Bryce, including the following topics: Introduction (0:00) Optimizing the Role of Hormonal Therapy in the Care of Patients with Prostate Cancer — Dr Bryce (2:41) Other Available and Emerging Therapeutic Approaches — Dr Agarwal (35:16) CME information and select publications

Featuring perspectives from Dr Erika Hamilton and Dr Shanu Modi, including the following topics: Introduction (0:00) Considerations in the Care of Patients with Localized HER2-Positive Breast Cancer — Dr Modi (0:58) Contemporary Management of HER2-Positive Metastatic Breast Cancer — Dr Hamilton (25:51) CME information and select publications

Featuring perspectives from Dr Kristen K Ciombor and Dr John Strickler, including the following topics: Introduction (0:00) Current and Future Role of Immune Checkpoint Inhibitors in the Management of Colorectal Cancer (CRC) — Dr Ciombor (3:58) Other Recent Advances in CRC Management — Dr Strickler (32:57) CME information and select publications

Featuring perspectives from Dr Adam M Brufsky and Dr Kevin Kalinsky, including the following topics: Introduction (0:00) Current and Future Role of TROP2-Directed Antibody-Drug Conjugates in Therapy for Triple-Negative Breast Cancer (TNBC) — Dr Brufsky (5:08) Established Treatment Paradigm for Localized and Metastatic TNBC — Dr Kalinsky (35:20) CME information and select publications

Featuring perspectives from Dr Yelena Y Janjigian and Dr Samuel J Klempner, including the following topics: Introduction (0:00) Role of Anti-PD-1/PD-L1- and CLDN18.2-Directed Antibodies in the Management of Gastroesophageal Cancers — Dr Klempner (5:52) Management of HER2-Positive Gastroesophageal Cancers — Dr Janjigian (28:20) CME information and select publications

Featuring perspectives from Dr Deborah K Armstrong and Dr David M O'Malley, including the following topics: Introduction (0:00) PARP Inhibitors and Strategies Targeting Folate Receptor Alpha in Advanced Ovarian Cancer — Dr Armstrong (4:37) Other Novel Agents and Strategies for the Treatment of Advanced Ovarian Cancer — Dr O'Malley (35:18) CME information and select publications

Host: Steve Jackson, PharmD Guest: Nisha Joseph, MD This is a non-certified educational series produced and controlled by ReachMD. As BCMA-directed therapies move into earlier lines of care, more patients with relapsed and refractory (R/R) multiple myeloma are entering a treatment space with limited consensus on optimal sequencing strategies. In this conversation with Dr. Steve Jackson, Dr. Nisha Joseph explores how disease biology, immune exhaustion, prior treatment response, and patient-specific factors can guide therapy selection in this population. She's an Associate Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine in Atlanta.

Featuring perspectives from Dr Terence Friedlander and Dr Daniel P Petrylak, including the following topics: Introduction (0:00) Role of Immunotherapeutic Strategies in the Management of Nonmetastatic Urothelial Bladder Cancer (UBC); Emerging Utility of Circulating Tumor DNA Evaluation — Dr Friedlander (3:53) Other Novel Agents and Strategies for Nonmetastatic and Metastatic UBC — Dr Petrylak (26:41) CME information and select publications

Featuring perspectives from Dr Hans Lee and Dr Noopur Raje, including the following topics: Introduction (0:00) Integrating Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies into the Management of Relapsed/Refractory Multiple Myeloma (R/R MM) — Dr Raje (4:30) Antibody-Drug Conjugates and Other Emerging Therapies for R/R MM — Dr Lee (28:33) CME information and select publications

In this first part of a special two-episode series of TOGA's Conversations in Lung Cancer Research podcast, A/Prof Deme Karikios, a Medical Oncologist at the Nepean Hospital in NSW, is joined by Prof Ken O'Byrne, a Consultant and Professor in Medical Oncology at the Princess Alexandra Hospital and the Queensland University of Technology, and A/Prof Rachel Roberts-Thomson, a Medical Oncologist at The Queen Elizabeth Hospital and Cancer Care Adelaide. The panel discusses the recent, groundbreaking broad PBS listing of certain immunotherapy agents in Australia, including the removal of 'once in a life time' rule. This major structural shift moves oncology prescribing away from rigid, indication-specific silos and toward clinician discretion guided by a patient's individual biology and the best available clinical evidence. This episode also covers what this means for advanced and metastatic thoracic malignancies, the biological rationale behind single versus doublet immunotherapy, and the practicalities of managing these clinical decisions. Podcast Sponsor Note: This podcast was proudly sponsored by Bristol Myers Squibb. All development and editorial decisions were made independently by the speakers. Resource Links: CM816 https://www.nejm.org/doi/full/10.1056/NEJMoa2202170 CM9LA https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30641-0/abstract CM227-https://www.nejm.org/doi/full/10.1056/NEJMoa1910231 CM227 was a clinical trial that examined ipi/nivo, nivo alone or chemotherapy in pts with NSCLC with PD-L1 expression level of 1%   (00:00) Welcome and Acknowledgement (02:00) New PBS Listing Explained (04:18) Defining Advanced and Sensitive (07:18) Dual vs Single Immunotherapy (12:27) Early Stage and Recurrence (14:26) Duration Stopping and Restarting (20:57) Other Thoracic Cancers (23:55) System Impact and Wrap Up Support TOGAThank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify.---------------Connect with TOGAAttend an Event: https://thoraciconcology.org.au/events/Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/Follow UsLinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/X (Twitter): https://x.com/TOGAANZInstagram: https://www.instagram.com/togaanz/YouTube: https://www.youtube.com/@Thoracic_Oncology---------------Acknowledgement of CountryThe Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.

Featuring perspectives from Dr John N Allan and Dr Adam Kittai, including the following topics: Introduction (0:00) Current Management of Newly Diagnosed Chronic Lymphocytic Leukemia — Dr Allan (8:47) Noncovalent Bruton Tyrosine Kinase Inhibitors and Other Novel Strategies — Dr Kittai (38:14) CME information and select publications

In collaboration with ROESCG, we introduce a new series, Cancer Careers! Today, we're joined by Dr. Chloe Lim, a 5th-year Medical Oncology Co-Lead Resident at the University of British Columbia. She takes us through how she co-founded the Learn Oncology podcast (the one you're listening to right now!), as well as her journey to Medical Oncology.

Featuring perspectives from Dr Manali Kamdar, Dr Krish Patel and Dr Gilles Salles, including the following topics: Introduction (0:00) Antibody-Drug Conjugates and Other Novel Strategies for the Management of Diffuse Large B-Cell Lymphoma (DLBCL) — Prof Salles (7:05) Current and Future Role of Monoclonal and Bispecific Antibodies in the Management of DLBCL — Dr Patel (26:21) Chimeric Antigen Receptor (CAR) T-Cell Therapy for DLBCL — Dr Kamdar (43:12) CAR T-Cell Therapy for Follicular Lymphoma (FL) — Prof Salles (1:08:33) Other Approved and Emerging Novel Therapies for FL — Dr Patel (1:24:44) Integrating Bispecific Antibodies into the Management of FL — Dr Kamdar (1:41:34) CME information and select publications

Featuring perspectives from Dr Eileen M O'Reilly and Dr Philip A Philip, including the following topics: Introduction (0:00) Optimal Incorporation of Chemotherapy into the Management of Advanced Pancreatic Cancer — Dr Philip (7:27) Other Available and Emerging Novel Approaches for Pancreatic Cancer — Dr O'Reilly (28:05) CME information and select publications

Send us Fan MailS4E5 The Oncology Journal Club Podcast The Oncology Journal Club team returns with Part 2 of its ASCO 2026 coverage, delivering a whirlwind tour through some of the most interesting studies presented across gastrointestinal, breast, lung, genitourinary, gynaecological, skin and haematological cancers.Craig Underhill, Kate Clarke and Christopher Jackson discuss emerging data on ctDNA-guided treatment strategies, exercise as adjuvant therapy, genomic testing in breast cancer, novel antibody-drug conjugates, immunotherapy advances, de-escalation studies and potential new standards of care. They also explore the growing role of precision medicine, evolving treatment sequencing strategies and the challenges facing the global oncology workforce.Along the way, expect the usual OJC banter, ASCO bingo, questionable drug pronunciations and a recurring tribute to Qantas pyjamas!The Oncology Journal Club Podcast is hosted by Professor Craig Underhill, Dr Kate Clarke and Professor Chris Jackson, and proudly produced by The Oncology NetworkVisit oncologynetwork.com.au for Show Notes, to send us Voice Notes and more information. And to download your bingo card if you'd like to play along with the team!

Welcome to Episode 8 of our monthly GU Cast Journal Club! Today we focus on two very important papers in localised prostate cancer and metastatic bladder cancer. The landmark 15 year update of the PROTECT trial, published in NEJM in 2023, and the breakthrough EV-301 trial which heralded enfortumab vedotin in progressive metastatic bladder cancer, published in NEJM in 2021.We are delighted to welcome back our GU Cast Journal Club Editors, Dr Carlos Delgado (Mexico City, MEX), and Dr Elena Berg (Munich, GER), along with main GU Cast Hosts, Renu Eapen and Declan Murphy. Links to papers below:1. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer NEJM 20232. Enfortumab Vedotin in Previously Treated Advanced Urothelial CarcinomaNEJM 2021Even better on our YouTube channelAbout GU Cast Journal Club:Each month, two papers are discussed, each of which are of importance to the GU Oncology community. These may be recent papers, or occasionally we will chose a classic landmark paper in GU Oncology. The objective is to draw attention to important papers in GU Oncology, and critique these in a robust manner. The key target audience is trainees working in Urology, Medical Oncology, Radiation Oncology, Nuclear Medicine, and diagnostic specialties such as Radiology and Pathology. But any of our regular audience are likely to enjoy this Journal Club series.

Send us Fan MailA cancer diagnosis can change everything in an instant. One conversation. Three words: "You have cancer." Suddenly, patients and families are faced with uncertainty, fear, and countless questions about what comes next.In this episode of MedStar Health DocTalk, host Debra Schindler sits down with medical oncologist and hematologist Dr. Ankit Madan of MedStar Southern Maryland Hospital Center, to discuss the critical first steps after a cancer diagnosis. Dr. Madan explains how patients move from diagnosis to treatment, how cancer is staged, and why building a multidisciplinary care team is essential for the best possible outcomes.The conversation explores the emotional impact of hearing a cancer diagnosis, the importance of patient navigators, social workers, nutritionists, mental health professionals, and the role patients play as active partners in their own care. Dr. Madan also discusses treatment advances, clinical trials, immunotherapy breakthroughs, second opinions, and practical advice for patients and families navigating one of life's most challenging journeys.Whether you or a loved one has recently been diagnosed with cancer, this episode offers guidance, reassurance, and expert insight into what happens after the diagnosis—and how patients can move forward with confidence and support.Topics covered:• Coping with the emotional impact of a cancer diagnosis• Understanding cancer staging and treatment planning• The role of biopsies, CT scans, PET scans, and additional testing• Building a multidisciplinary cancer care team• Patient navigators, social workers, and support services• Shared decision-making and patient autonomy• When to seek a second opinion• Clinical trials and emerging cancer treatments• Immunotherapy and advances in cancer care• Nutrition, exercise, and mental health during treatment• Cancer survivorship and ongoing surveillanceTo learn more about cancer care at MedStar Health, visit MedStarHealth.org/Cancer.For more episodes of MedStar Health DocTalk, go to medstarhealth.org/doctalk.

In today's episode, we welcomed Joshua Richter, MD, to preview some of the top multiple myeloma presentations anticipated at the 2026 EHA Congress. Richter is an associate professor of medicine in the Division of Hematology and Medical Oncology at the Tisch Cancer Institute and director of Multiple Myeloma at the Blavatnik Family-Chelsea Medical Center at Mount Sinai in New York, New York.In the exclusive interview, Dr Ricther highlighted some of the key abstracts he's looking forward to seeing presented at EHA 2026, including primary data from an additional study of a bispecific antibody­–based combination being evaluated in the early-relapse setting and longer-term analyses from pivotal phase 3 studies. Richter also shared the key themes and trends he expects to see during the meeting in Stockholm, Sweden.

How This Is Building Me, hosted by world-renowned oncologist D. Ross Camidge, MD, PhD, is a podcast focused on the highs and lows, ups and downs of all those involved with cancer, cancer medicine, and cancer science across the full spectrum of life's experiences.In this episode, guest host Erin Schenk, MD, PhD, at the University of Colorado Anschutz in Aurora, an associate professor of medicine in the Division of Medical Oncology, sat down with D. Ross Camidge, MD, PhD, to highlight Dr Camidge's storied career and life. Driven by a relentless curiosity that often manifested in him "interrogating" those around him, Camidge chose a career in medicine because of the immediate effect he saw it could have on people's lives.His path included a formative gap year working at McDonald's and serving as a caregiver for a man with cerebral palsy. After studying at Oxford, he faced a significant professional and personal low when pursuing his PhD at Cambridge. Struggling with a difficult project, he persevered by pivoting his research and finding resilience through peers, eventually returning to practicing clinical medicine and finding his calling in oncology due to its unique overlap of molecular biology and opportunities for deep patient connection.Seeking further opportunities, Dr Camidge moved to the United States to lead the lung cancer program at the University of Colorado School of Medicine. He became a pivotal figure in the development of targeted therapies, specifically crizotinib for ALK-positive lung cancer. Beyond drug development, he championed the use of molecular profiling and established a global remote second opinion program.In 2022, Dr Camidge's perspective shifted profoundly following his own lung cancer diagnosis. This experience forced him to evolve from a "questioning machine" into someone more amenable to accepting love and support. He now integrates this dual perspective into his work, emphasizing that oncology must go beyond science to address the human experience of treating real people.

This episode is deeply personal to me.As the daughter of Indian immigrants, a breast surgeon, and a breast cancer survivor, I've seen firsthand how difficult it can be for our community to talk openly about health issues—especially breast cancer.Too often, conversations are delayed by fear, stigma, modesty, or the belief that we should simply "stay strong" and endure.But when it comes to breast cancer:

In this Part 1 of 2 ASCO 2026 Highlights episodes, hosts Dr. Narjust Florez and Dr. Stephen Liu are joined by Dr. Alice Shaw and Dr. Jonathan Goldman to review some of the most impactful targeted therapy data presented at the 2026 ASCO Annual Meeting. The discussion explores the practice-changing LIBRETTO-432 trial in early-stage RET-positive NSCLC, long-term outcomes with lorlatinib in ALK-positive disease, emerging data for neladalkib, and promising results for sunvozertinib in EGFR exon 20 insertion–positive NSCLC, highlighting how these findings may influence treatment decisions across disease stages. Guests: Dr. Alice Shaw. is a Professor of Medicine at Harvard Medical School, Chair of Medical Oncology, and a thoracic oncologist at Dana Farber Cancer Institute. She is widely recognized as a pioneer in the field of ALK-positive non-small cell lung cancer, having led landmark clinical trials that established crizotinib, ceritinib, and lorlatinib as standards of care. Dr. Jonathan W. Goldman is a Professor of Medicine and thoracic oncologist at the UCLA David Geffen School of Medicine, where he serves as a principal investigator in the Phase I drug development program. Dr. Goldman has been at the forefront of early-phase oncology trials across multiple tumor types, with a particular focus on novel therapeutics in lung cancer, and he was the presenting author of Libretto 432 at the plenary session at the 2026 ASCO

How This Is Building Me, hosted by world-renowned oncologist D. Ross Camidge, MD, PhD, is a podcast focused on the highs and lows, ups and downs of all those involved with cancer, cancer medicine, and cancer science across the full spectrum of life's experiences.In this episode, Dr Camidge sat down with Karen L. Reckamp, MD, director of Medical Oncology, associate director of Clinical Research, and the medical oncology director of the Lung Institute at Cedars Sinai in Los Angeles, California.Drs Camidge and Reckamp discussed Dr Reckamp's journey as an oncology specialist and now a caregiver for her husband, who has cancer. Reckamp's career was inspired by her family's history with BRCA-related cancers. She pursued an academic path that eventually led her to Los Angeles, where she became a leader in thoracic oncology during an era of genomic breakthroughs.In late 2024, her husband, a fellow oncologist, was diagnosed with pancreatic cancer shortly after a clear annual scan. Reckamp described the jarring transition of receiving the diagnosis and the ensuing emotions balanced with medical pragmatism. Bob underwent intensive treatments that have affected his physical health and daily life.Reckamp offered a candid look at the dual role of a physician-caregiver. She continues to work, however, her husband's cancer diagnosis has changed her practice. Now, she is more sensitive to chemotherapy toxicities in her patients that she might have previously minimized. She also highlighted the invisible load of caregivers who must manage their own emotions and remain available for patient needs.Ultimately, Reckamp emphasized the necessity of a support network, crediting their long-time nanny and overall community with maintaining her family's stability. By allowing different people to hold different pieces of the emotional burden, Reckamp shared that her family is finding a way to move forward amidst the uncertainty of this cancer diagnosis.

Speakers:Mital Patel, MD, Director of Hematology and Medical Oncology, Dignity Health Cancer Institute at St. Joseph's Hospital and Medical CenterRonald Gagliano, MD, System Vice President, Oncology Service Line, Physician Executive and Chairman, Department of Surgery, Dignity Health Medical Group ArizonaModeratorAnkita Sagar, MD, MPH, FACP, FAMWA, System Vice President, Clinical Transformation and Well-Being

Entrepreneur René Beltjens pedals 7,000km from Estonia to Gibraltar with 2Wheels4Purpose to raise €1 million for breast cancer research at Saint‑Luc. René Beltjens is a brilliant business man, co‑founder of Alter Domus amongst many more accolades, but as a young family man he had to endure the very hardest family situation. His young wife was diagnosed with breast cancer aged just 30 right after the birth of their third child. Due to a new treatment at that time, she was given another few years of life, priceless for their entire young family. René is now giving back to Saint-Luc, the place where she was treated, by undertaking a cross-section cycle of Europe with  teammates Sander van der Fluit and Marc Bijlsma to raise €1m towards specific breast cancer research. Two Wheels for Purpose began with a simple dinner between lifelong friends and grew into an ambitious cycling expedition from Tallinn to Gibraltar, 7,000km crossing 22 countries, matching physical endurance with the resilience of patients and families fighting cancer. Professor François Duhoux, Head of Medical Oncology at Cliniques universitaires Saint-Luc in Brussels, will be leading the research project from the money raised. Breast cancer treatment has evolved from a one-size-fits-all model to increasingly personalised care, using tumour characteristics, mutations and 3D organoids, ‘avatars' of the tumour, to test which drugs may work best before treatment begins. Prof Duhoux also stressed that cancer care is no longer only about treating the tumour. At Saint-Luc's Institut Roi Albert II, patients are supported by doctors, nurses, psychologists, dieticians, physiotherapists, social workers and volunteers, with art therapy and other wellbeing tools helping patients better tolerate treatment and improve quality of life. “We don't treat tumours, we treat patients with cancer.” That holistic approach was echoed by Tessa Schmidburg, Secretary General of Fondation Saint-Luc, who described the foundation as a bridge between generosity and progress. She said its role is to accelerate “the excellence and the humanity” of care, supporting medical research, innovation and patient wellbeing through donations from individuals, families and companies. “It's not a Tour de France Andy, it's much harder.” Andy Schleck, former Tour de France winner lost his mother quite recently to cancer and in her final year during visits, Andy would always try to transit positive ideas. That was until she told her son that enduring the treatments is much harder than a Tour de France. Andy does have a little cycling advice (and perhaps it's not just for the road) for René and his fellow cyclists: “When the road is long you go kilometre by kilometre. When the road gets hard you focus on the next corner.” “Cancer is a family disease.” Cancer reshapes family life during the treatment, and also aftwards. René described commuting between Luxembourg and Brussels, protecting weekends as sacred time with his children, and navigating the fear and uncertainty that comes with a diagnosis in the family. He also explained why his daughters' decisions about genetic screening raised difficult questions about health, privacy and insurance, even though medical guidance strongly supports testing where there is a family history. “The first thing is awareness.” Nimkee Gupta was diagnosed with aggressive ovarian cancer in 2023. She spoke candidly about treatment in both India and Luxembourg, the difficulty in recognising ovarian cancer, and the importance of language in changing how people respond to the disease. Nimkee also speaks about how ovarian cancer and other women's cancers remain under-researched. Data, scale and gender bias all matter. “There should be no shame through cancer.” Nimkee is passionate about the healing power of music, art, movement and food became part of her recovery, and she described learning to use minimal mobilisation, swimming, and Ayurveda as part of a sustainable approach to wellbeing. The conversation offered a thoughtful reminder that treatment does not end when chemotherapy or similar ends; recovery continues in the body, mind and family circle. Prof Duhoux also highlighted a crucial public-health message: breast cancer screening rates remain too low, and early detection makes a major difference. Beltjens said the goal of Two Wheels for Purpose aims to also create a ripple effect - a community of ambassadors who speak openly about cancer and encourage others to act. Purpose grows when people turn private pain into public progress. https://www.2wheels4purpose.com/ https://www.fondationsaintluc.be/

Breast Cancer Briefing, hosted by Sara Nunnery, MD, MSCI, a breast medical oncologist and the director of Breast Cancer Research at Tennessee Oncology in Nashville, is a podcast series that breaks down the latest news in breast cancer research, one conversation at a time.In part 2 of this conversation, filmed live onsite at the 43rd Annual Miami Breast Cancer Conference, Dr Nunnery sat down with Irene Morae Kang, MD, an assistant professor in the Department of Medical Oncology & Therapeutics Research and the medical director of Women's Health Medical Oncology at City of Hope Orange County in Irvine, California.Their discussion focuses on the rapidly evolving treatment paradigm for first-line metastatic triple-negative breast cancer (TNBC), including the emergence of new data that is shifting standards of care. Dr Kang explained that TNBC is defined by the absence of estrogen, progesterone, and HER2 receptors, which historically restricted treatment options to non-targeted chemotherapy. A primary focus of the conversation was the role of PD-L1 expression and the use of immunotherapy. Dr Kang described PD-L1 as a checkpoint inhibitor protein on cancer cells that shuts off the immune system. By blocking this protein, oncologists can keep the body's T-cells vigilant to fight the cancer. However, she noted that immunotherapy is typically reserved for the approximately 40% of patients who express PD-L1 and may be contraindicated for those with active autoimmune diseases or a history of severe immune-related toxicities.The dialogue transitioned into the use of antibody-drug conjugates (ADCs). Dr Kang reviewed data from major trials using TROP2-targeting ADCs in the first-line setting. Dr Kang emphasized the importance of using these highly effective agents early, as many patients with TNBC do not survive to receive a second line of therapy.Finally, Dr Kang highlighted the distinct toxicity profiles and administration schedules that guide clinical decision-making. Although sacituzumab govitecan-hziy (Trodelvy) is frequently associated with neutropenia and alopecia, the primary toxicities associated with datopotamab deruxtecan-dlnk (Dato-DXd; Datroway) are stomatitis and ocular adverse effects like dry eye. Using Dato-DXd in practice requires a rigorous prophylactic regimen, including steroid mouthwash and lubricating eye drops. Ultimately, Dr Kang noted that because efficacy appears similar between the 2 ADCs, the choice often rests on the patient's lifestyle, their ability to adhere to preventative AE protocols, and infusion schedule preference.

Breast Cancer Briefing, hosted by Sara Nunnery, MD, MSCI, a breast medical oncologist and the director of Breast Cancer Research at Tennessee Oncology in Nashville, is a podcast series that breaks down the latest news in breast cancer research, one conversation at a time.In part 2 of this conversation, filmed live onsite at the 43rd Annual Miami Breast Cancer Conference, Dr Nunnery sat down with Neil M. Iyengar, MD, an associate professor and co-director of Breast Medical Oncology in the Department of Hematology and Medical Oncology at the Emory University School of Medicine, as well as the director of Survivorship Services at the Winship Cancer Institute of Emory University in Atlanta, Georgia.Their conversation highlighted the evolving integration of GLP-1 agonists into the breast cancer treatment armamentarium.

This episode features Marwan G. Fakih, MD - Medical Oncologist, Professor, Department of Medical Oncology & Therapeutics Research, Deputy Director, City of Hope Comprehensive Cancer Center, Division Chief, GI Medical Oncology, Co-director, Gastrointestinal Cancer Program at City of Hope. Here he shares his thoughts around potentially screening younger patients, due higher rates of colon cancer. He also discusses the importance of educating patients to not overlook potential symptoms, clinical trials, and more.

This episode features Marwan G. Fakih, MD - Medical Oncologist, Professor, Department of Medical Oncology & Therapeutics Research, Deputy Director, City of Hope Comprehensive Cancer Center, Division Chief, GI Medical Oncology, Co-director, Gastrointestinal Cancer Program at City of Hope. Here he shares his thoughts around potentially screening younger patients, due higher rates of colon cancer. He also discusses the importance of educating patients to not overlook potential symptoms, clinical trials, and more.

Breast cancer in young women is rising—and many are left with more questions than answers.In this episode, we break down:✔️ Why breast cancer happens in younger women✔️ What symptoms you should never ignore✔️ Genetics, fertility, and treatment decisions✔️ The truth behind common mythsAnd most importantly—

Democracy in action! This month's GU Cast Journal Club papers were chosen by an audience vote at our GU Cast Live Event at EAU in London. Therefore today we focus on first, the landmark proPSMA paper which established the superior accuracy of PSMA PET/CT for staging unfavourable intermediate and high-risk prostate cancer (Lancet 2020). Then for something completely different, we dig out a paper called "Penile fractures - the merry price of Christmas", published in BJUI 2020. Thanks very much to our live audience for this one!We are delighted to welcome back our GU Cast Journal Club Editors, Dr Carlos Delgado and Dr Elena Berg who joins us in studio for the first time. Elena has just moved to Melbourne to join Carlos doing a Fellowship with GU Cast hosts, Renu Eapen and Declan Murphy. Links to papers below:1. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 20202. Penile fractures: the price of a Merry Christmas BJUI 2023GU Cast Journal Club is supported by our Partner, MSD, through an unrestricted educational grant.Even better on our YouTube channelAbout GU Cast Journal Club:Each month, two papers are discussed, each of which are of importance to the GU Oncology community. These may be recent papers, or occasionally we will chose a classic landmark paper in GU Oncology. The objective is to draw attention to important papers in GU Oncology, and critique these in a robust manner. The key target audience is trainees working in Urology, Medical Oncology, Radiation Oncology, Nuclear Medicine, and diagnostic specialties such as Radiology and Pathology. But any of our regular audience are likely to enjoy this Journal Club series.

Breast Cancer Briefing, hosted by Sara Nunnery, MD, MSCI, a breast medical oncologist and the director of Breast Cancer Research at Tennessee Oncology in Nashville, is a podcast series that breaks down the latest news in breast cancer research, one conversation at a time.In today's episode, filmed live onsite at the 43rd Annual Miami Breast Cancer Conference, Dr Nunnery sat down with Neil M. Iyengar, MD, an associate professor and co-director of Breast Medical Oncology in the Department of Hematology and Medical Oncology at the Emory University School of Medicine, as well as the director of Survivorship Services at the Winship Cancer Institute of Emory University in Atlanta, Georgia.Their conversation centered around lifestyle and medical interventions pertinent to breast cancer survivorship. Dr Iyengar explained that although endocrine therapies can be life-saving, they disrupt estrogen signaling, which can lead to cardiometabolic dysfunction, including increased risks for diabetes, heart disease, and bone health issues. He noted that weight gain associated with these treatments is often tied to the induction of a post-menopausal state, which disrupts energy homeostasis and promotes inflammation.A key theme of the conversation was Dr Iyengar's explanation of a "drug development paradigm" for lifestyle changes. Rather than offering generic advice, his research focuses on precision lifestyle interventions, treating diet and exercise as prescribed medical therapies with specific "doses". He highlighted that body mass index (BMI) is an insufficient tool for risk stratification, as high body fat despite a normal BMI is a significant risk factor for cancer recurrence.The discussion also covered the rising use of GLP-1 receptor agonists to manage metabolic health. These drugs replicate natural hormones to maintain glycemic balance and reduce hunger. Dr Iyengar addressed the black box warning for thyroid cancer associated with this class of drugs, noting that although the data are mixed, the protective benefits against obesity-related cancers appear to outweigh the risks. Finally, he emphasized that exercise is a critical tool for managing treatment adverse effects like fatigue, noting that although starting is difficult, the "return on investment" for patient health is immense.

In today's episode, we spoke with Ticiana Leal, MD, about variability in community practice and evolving treatment strategies for patients with small cell lung cancer (SCLC). Dr Leal is a professor and director of the Thoracic Medical Oncology Program in the Department of Hematology and Medical Oncology at Emory University School of Medicine, as well as the medical director of the Clinical Trials Office at Winship Cancer Institute in Atlanta, Georgia.In our exclusive interview, Dr Leal began by discussing how SCLC management can differ widely across community settings according to how patients present. Leal emphasized the importance of quickly confirming a patient's diagnosis and initiating treatment to avoid missing the critical window where chemotherapy could provide meaningful clinical benefit. However, Leal noted that the field still lacks predictive biomarkers to guide treatment selection. Accordingly, current strategies, including chemoimmunotherapy, maintenance approaches, and second-line options like tarlatamab-dlle (Imdelltra) and lurbinectedin (Zepzelca) are largely chosen based on clinical factors such as disease burden, comorbidities, and patient preferences.The conversation then shifted to the challenge of treating patients who may not meet traditional clinical trial eligibility criteria due to poor performance status, comorbidities, or social vulnerabilities. Leal stated that a multidisciplinary approach, including collaboration with supportive care teams, is essential to optimize outcomes for these patients. She noted that potential solutions to restrictive trial eligibility criteria may include decentralizing trials, improving collaboration between academic and community centers, and providing additional patient support such as transportation and care navigation services.Looking ahead, Leal emphasized the need for community practices to prepare for emerging therapies, including antibody-drug conjugates and novel immunotherapy approaches. Successfully integrating these treatments into everyday practice will require education, infrastructure development, and multidisciplinary collaboration, Leal imparted.

With the increasing incidence of colorectal cancer in those less than 50 years of age, one must wonder how many patients present with a Stage IV diagnosis. Take a deep dive with us discussing the management of metastatic colorectal cancer by joining our team and guests, Drs. Cathy Eng, Michael D'Angelica, and Nina Sanford.Hosts: - Dr. Janet Alvarez - General Surgery Resident at New York Medical College/Metropolitan Hospital Center- Dr. Wini Zambare – General Surgery Resident at Weill Cornell Medical Center/New York Presbyterian- Dr. Philip Bauer, Assistant Professor of Surgery, Division of Colon and Rectal Surgery, The Ohio State University Wexner Medical Center, Arthur G. James Cancer Hospital-  Dr. J. Joshua Smith MD, PhD, Chair, Department of Colon and Rectal Surgery at MD Anderson Cancer Center Guest Speakers:- Dr. Michael D'Angelica MD, FACS – Hepatopancreatobiliary Surgery, Memorial Sloan Kettering Cancer Center, Enid A. Haupt Chair in Surgery, Vice Chair, Education- Dr. Cathy Eng MD, FACP - Division of Hematology and Oncology, Vanderbilt-Ingram Cancer Center, David H. Johnson Endowed Chair in Surgical and Medical Oncology, Professor of Medicine, Hematology and Oncology, VICC Associate Director for Strategic Relations and Research Partnerships, Executive Director, Young Adult Cancers Program - Dr. Nina Sanford, MD – Radiation Oncology, UT Southwestern Medical Center, Chief of Gastrointestinal Radiation Oncology Service, Associate Professor Learning Objectives:1.     Review the epidemiology, prognosis, and common metastatic patterns of metastatic colorectal cancer (mCRC).2.     Discuss the role of systemic chemotherapy and targeted therapies in the first- and subsequent-line treatment of mCRC, including the impact of molecular biomarkers such as MSI/MMR, RAS, BRAF, and HER2.3.     Evaluate the indications and timing of surgical and locoregional therapies for metastatic colorectal cancer, particularly in patients with liver-limited or oligometastatic disease.4.     Describe the multidisciplinary management of mCRC, including the roles of radiation therapy, systemic therapy sequencing, and palliative interventions to optimize outcomes and quality of life.References:Singh, M., Morris, V. K., Bandey, I. N., Hong, D. S. & Kopetz, S. Advancements in combining targeted therapy and immunotherapy for colorectal cancer. Trends Cancer 10, 598–609 (2024). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/38821852/Napolitano, S. et al. BRAFV600E mutant metastatic colorectal cancer: Current advances in personalized treatment and future perspectives. Cancer Treat. Rev. 134, (2025). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40009904/Ciardiello, F. et al. Clinical management of metastatic colorectal cancer in the era of precision medicine. CA. Cancer J. Clin. 72, 372–401 (2022). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/35472088/Kim, S. Y. & Kim, T. W. Current challenges in the implementation of precision oncology for the management of metastatic colorectal cancer. ESMO Open 5, e000634 (2020). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/32188714/Biller, L. H. & Schrag, D. Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review. JAMA 325, 669–685 (2021). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/33591350/Smith, J. J. et al. Genomic stratification beyond Ras/B-Raf in colorectal liver metastasis patients treated with hepatic arterial infusion. Cancer Med. 8, 6538–6548 (2019). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/31503397/Saadat, L. V. et al. Hepatic Artery Infusion Chemotherapy Compared to Transarterial Radioembolization For Unresectable Colorectal Liver Metastases. Ann. Surg. 10.1097/SLA.0000000000006851 doi:10.1097/SLA.0000000000006851. PubMed Link: https://pubmed.ncbi.nlm.nih.gov/?term=10.1097/SLA.0000000000006851 (Linked via DOI search as the direct PMID is still indexing)Xiao, A. & Fakih, M. KRAS G12C Inhibitors in the Treatment of Metastatic Colorectal Cancer. Clin. Colorectal Cancer 23, 199–206 (2024). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/38825433/André, T. et al. Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer. N. Engl. J. Med. 383, 2207–2218 (2020). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/33264544/Morris, V. K. et al. Treatment of Metastatic Colorectal Cancer: ASCO Guideline. J. Clin. Oncol. 41, 678–700 (2023). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/36252154/Xu, Z. et al. Treatments for Stage IV Colon Cancer and Overall Survival. J. Surg. Res. 242, 47–54 (2019). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/31071604/Smith, J. J. & D'Angelica, M. I. Surgical Management of Hepatic Metastases of Colorectal Cancer. Hematol. Oncol. Clin. North Am. 29, 61–84 (2015). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/25475573/Strickler, J. H. et al. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. Lancet Oncol. 24, 496–508 (2023). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/37142372/Kruijssen, D. E. W. van der et al. Upfront resection versus no resection of the primary tumor in patients with synchronous metastatic colorectal cancer: the randomized phase III CAIRO4 study conducted by the Dutch Colorectal Cancer Group and the Danish Colorectal Cancer Group. Ann. Oncol. 35, 769–779 (2024). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/38852675/Hitchcock, K. E., Romesser, P. B. & Miller, E. D. Local Therapies in Advanced Colorectal Cancer. Hematol. Oncol. Clin. North Am. 36, 553–567 (2022). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/35562258/Hitchcock, K. E. et al. Alliance for clinical trials in Oncology (Alliance) trial A022101/NRG-GI009: a pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer: evaluating radiation, ablation, and surgery (ERASur). BMC Cancer 24, 201 (2024). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/38350888/Adam, R. et al. Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet): results from a multicentre, open-label, prospective, randomised controlled trial. The Lancet 404, 1107–1118 (2024). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/39306468/Elez, E. et al. Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer. N. Engl. J. Med. 392, 2425–2437 (2025). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40444708/***Fellowship Application Link: https://forms.gle/QSUrR2GWHDZ1MmWC6Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.  If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listenBehind the Knife Premium:General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-reviewTrauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlasDominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkshipDominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotationVascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-reviewColorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-reviewSurgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-reviewCardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-reviewDownload our App:Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

In today's episode, we spoke with Colin Vale, MD. Dr Vale is an assistant professor in the Department of Hematology and Medical Oncology at the Emory University School of Medicine in Atlanta, Georgia.In our exclusive interview, Dr Vale discussed data from a phase 2 trial (NCT03263572) evaluating blinatumomab (Blincyto) plus ponatinib (Iclusig) in patients with Philadelphia chromosome–positive B-cell acute lymphoblastic leukemia. In addition to underscoring the findings and their clinical significance, Vale expanded on how the combination can improve patient quality of life by helping patients avoid procedures like allogeneic stem cell transplant.

In today's episode, we spoke with Anne Chiang, MD, PhD, to discuss the rapidly evolving treatment landscape in small cell lung cancer (SCLC) and what this new era of innovation means for patients. Dr Chiang is an associate professor of medicine in the Section of Medical Oncology at Yale School of Medicine and associate cancer center director for clinical initiatives at Yale Cancer Center in New Haven, Connecticut.In our exclusive interview, Chiang reflected on how the field has shifted since the introduction of chemoimmunotherapy in 2018, highlighting improvements in median overall survival and the emergence of long-term responders in extensive-stage disease. Chiang also explored the growing understanding of disease heterogeneity, and the evolution of biomarker-informed strategies like under evaluation in the phase 2 S2409 PRISM trial (NCT06769126).Additionally, Chiang examined the clinical effect of DLL3-targeted therapies, including the recently approved bispecific antibody tarlatamab-dlle (Imdelltra), and how surface-targeting strategies are expanding options beyond traditional chemotherapy. Beyond efficacy, Chiang underscored the importance of individualized decision-making by assessing patient fitness beyond ECOG performance status, navigating treatment urgency in rapidly progressive disease, and balancing durability with toxicity when counseling patients on therapy.

Welcome to OncLive On Air®! I'm your host today, Courtney Flaherty.OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.In today's episode, Philippos Costa, MD, and Hari Deshpande, MD sat down to discuss and answer frequently asked questions about chondrosarcoma in honor of International Chondrosarcoma Awareness Day. This included common pitfalls in the diagnostic process for this rare, heterogenous bone malignancy; the central role of surgery as the primary treatment for localized chondrosarcoma; and the potential application of IDH1-targeted therapy, DR5 agonists, and other emerging targeted therapies in this sarcoma subtype.Dr Deshpande is an associate professor of medicine, clinical research team leader in sarcoma, and the director of Medical Oncology Inpatient Consult Service in the Section of Medical Oncology at Yale School of Medicine. Dr Costa is an oncologist and assistant professor of medicine (Medical Oncology and Hematology) at Yale School of Medicine._____That's all we have for today! Thank you for listening to this episode of OncLive On Air. Check back throughout the week for exclusive interviews with leading experts in the oncology field.For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.OncLive is also on social media. On X and BlueSky, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.If you liked today's episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!Thanks again for listening to OncLive On Air.*OncLive On Air is available on: Apple Podcasts, Spotify, CastBox, Podcast Addict, Podchaser, RadioPublic, and TuneIn.This content is a production of OncLive. The current episode was filmed in advance of Chondrosarcoma Day, observed on February 6, 2026

Dr. Bryant Lin is a primary care physician, educator, and researcher at Stanford University. In 2018, he founded CARE – the Center for Asian Health Research and Education. In 2023, CARE began a focused research effort investigating lung cancer in non-smoking Asians. In 2024, Dr. Lin was diagnosed with Stage 4 lung cancer, having never smoked in his life. After his diagnosis, Dr. Lin sprung into action. He began receiving care from Dr. Heather Wakelee – a Stanford oncologist specializing in lung cancer. Dr Wakelee is the Deputy Director of the Stanford Cancer Institute, the Division Chief of Medical Oncology, and a leader in the International Association for the Study of Lung Cancer. In this episode, we are privileged to be joined by both Dr. Lin and his oncologist, Dr. Wakelee.Over the course of our conversation, Dr. Lin describes the experience of receiving and living with a diagnosis that has been life changing for both him and his family. He details his remarkable efforts to leverage his diagnosis for the good of patients and rising medical professionals  — and explains how spiritual practices have helped sustain him through this difficult time. Dr. Wakelee shares her approach to first visits with patients facing daunting cancer diagnoses, how she approaches grief, and the unique privilege and challenge of treating a colleague. Together, the doctor and his physician explore the value of hope in cancer, the dangers of false hope, and the importance of maximizing meaning in life — however much time is left. In this episode, you'll hear about: 2:50 - Dr. Lin's experience of being diagnosed with stage 4 lung cancer despite having never smoked14:20 - Dr. Wakelee's approach to first visits with newly diagnosed lung cancer patients25:35 - Dr. Lin's experience of shifting from the mindset of “doctor” to the mindset of “patient” 30:30 - How a doctor's messaging can affect the patient's outlook on their diagnosis43:00 - The common themes prevalent across religions and spiritual orientations that support patients in the navigation of serious illness50:24 - Advice to doctors for finding deeper meaning in medicineListen to Dr. Lin's first appearance on The Doctor's Art. If you enjoyed this episode, please subscribe, rate, and review our show, available for free on Spotify, Apple Podcasts, or wherever you get your podcasts. If you know of a doctor, patient, or anyone working in health care who would love to explore meaning in medicine with us on the show, feel free to leave a suggestion in the comments or send an email to info@thedoctorsart.com.Copyright The Doctor's Art Podcast 2026